Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc (AYTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aytu Biopharma Inc 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 USA

www.aytubio.com Employees: 102 P: 720-437-6580

Description:

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado.

Key Statistics

Overview:

Market Capitalization, $K 8,486
Enterprise Value, $K 3,606
Shares Outstanding, K 6,149
Annual Sales, $ 81,000 K
Annual Net Income, $ -15,840 K
Last Quarter Sales, $ 16,570 K
Last Quarter Net Income, $ 1,470 K
EBIT, $ 140 K
EBITDA, $ 9,010 K
60-Month Beta -1.40
% of Insider Shareholders 2.77%
% of Institutional Shareholders 33.49%
Float, K 5,979
% Float 97.23%
Short Volume Ratio 0.07

Growth:

1-Year Return -51.75%
3-Year Return -95.46%
5-Year Return -99.30%
5-Year Revenue Growth 1,006.56%
5-Year Earnings Growth 99.59%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 11/13/24
Next Earnings Date 02/12/25
Earnings Per Share ttm -1.58
EPS Growth vs. Prev Qtr 75.61%
EPS Growth vs. Prev Year 86.49%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 01/06/23

AYTU Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -21.89%
Return-on-Assets % -5.37%
Profit Margin % -19.56%
Debt/Equity 0.56
Price/Sales 0.10
Price/Cash Flow N/A
Price/Book 0.28
Book Value/Share 4.85
Interest Coverage -1.94
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar